These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 1605715)

  • 1. Stereoisomeric [1,2-bis(3-hydroxyphenyl)ethylenediamine]platinum(II) complexes, Part III: Evaluation of the mammary tumor inhibiting properties.
    Schertl S; Gust R; Müller R; Spruss T; Schönenberger H
    Arch Pharm (Weinheim); 1992 Feb; 325(2):113-8. PubMed ID: 1605715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor inhibiting [1,2-bis(fluorophenyl)ethylenediamine]platinum(II) complexes, III: Evaluation of the mammary tumor inhibiting properties.
    Reile H; Spruss T; Müller R; Gust R; Bernhardt G; Schönenberger H; Engel J
    Arch Pharm (Weinheim); 1990 May; 323(5):301-6. PubMed ID: 2383173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mammary tumor inhibiting properties of the (S,S)-configurated [1,2-bis(4-hydroxyphenyl)ethylenediamine]dichloroplatinum(II) complex.
    Spruss T; Gust R; Müller R; Engel J; Schönenberger H
    Arch Pharm (Weinheim); 1990 Feb; 323(2):99-102. PubMed ID: 2334275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor inhibiting properties of stereoisomeric [1,2-bis(3-hydroxyphenyl)ethylenediamine]dichloroplatinum(II)-compl exe s, Part I: Synthesis.
    Jennerwein M; Gust R; Müller R; Schönenberger H; Engel J; Berger MR; Schmähl D; Seeber S; Osieka R; Atassi G
    Arch Pharm (Weinheim); 1989 Jan; 322(1):25-9. PubMed ID: 2730286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Aqua-1-(2,6-dichloro-4-hydroxyphenyl)-2-phenylethylenediamine] sulfatoplatinum(II) complexes with variable substituents in the 2-phenyl ring. 3. Investigation of breast cancer inhibiting properties.
    Gust R; Faderl M; Schönenberger H
    J Cancer Res Clin Oncol; 2000 Nov; 126(11):647-54. PubMed ID: 11079729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Platinum complexes with a selective action on estrogen receptor-positive mammary tumors.
    von Angerer E; Birnböck H; Knebel N
    Anticancer Drug Des; 1989 Jun; 4(1):21-35. PubMed ID: 2757751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Different response of murine and human mammary tumour models to a series of diastereoisomeric [1,2-bis(difluorophenyl) ethylenediamine]dichloroplatinum(II) complexes.
    Spruss T; Bernhardt G; Schickaneder E; Schönenberger H
    J Cancer Res Clin Oncol; 1991; 117(5):435-43. PubMed ID: 1890139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aqua[1,1-bis(4-hydroxyphenyl)-1,2-diamino-2-phenylethane]- sulfatoplatinum(II), a new compound for the treatment of the mammary carcinoma.
    Gust R
    Arch Pharm (Weinheim); 1994 Jan; 327(1):49-54. PubMed ID: 8117188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ring-substituted [1,2-bis(4-hydroxyphenyl)ethylenediamine]dichloroplatinum (II) complexes: compounds with a selective effect on the hormone-dependent mammary carcinoma.
    Karl J; Gust R; Spruss T; Schneider MR; Schönenberger H; Engel J; Wrobel KH; Lux F; Haeberlin ST
    J Med Chem; 1988 Jan; 31(1):72-83. PubMed ID: 3336035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl) ethylenediamine]dichloroplatinum(II), a compound with a specific activity on hormone-sensitive breast cancers--evidence for a diethylstilbestrol-like mode of action.
    Schlemmer R; Spruss T; Bernhardt G; Schönenberger H
    Arch Pharm (Weinheim); 1999 Feb; 332(2):59-69. PubMed ID: 10191716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor inhibiting properties of stereoisomeric [1,2-bis(3-hydroxyphenyl) ethylenediamine]dichloroplatinum(II)-complexes, Part II: Biological properties.
    Jennerwein M; Gust R; Müller R; Schönenberger H; Engel J; Berger MR; Schmähl D; Seeber S; Osieka R; Atassi G
    Arch Pharm (Weinheim); 1989 Feb; 322(2):67-73. PubMed ID: 2730292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mammary tumor inhibiting [1,2-bis(2,6-dihalo-3-hydroxyphenyl)ethylenediamine]platinum(II) complexes, III: Relationship between structure and estrogenic activity of the diamine ligands, their sulfatoplatinum(II) and diiodoplatinum(II) complexes.
    Gust R; Schönenberger H
    Arch Pharm (Weinheim); 1993 Jul; 326(7):405-13. PubMed ID: 8357303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine]- dichloroplatinum(II) act on the hormone-sensitive, murine breast cancer as a biological response modifier? Part 1: The MXT-M-3.2 breast cancer stimulates the growth of an identical second graft; [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine]dichloroplat inum (II) inhibits this process.
    Schlemmer R; Spruss T; Bernhardt G; Schönenberger H
    Arch Pharm (Weinheim); 2000 Mar; 333(2-3):69-71. PubMed ID: 10783521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [1, 2-Bis(2, 6-difluoro-3-hydroxyphenyl)ethylene-diamine]platinum(II) complexes, compounds for the endocrine therapy of breast cancer - mode of action I: antitumor activity due to the reduction of the endogenous estrogen level.
    Schertl S; Hartmann RW; Batzl-Hartmann C; Bernhardt G; Spruss T; Beckenlehner K; Koch M; Krauser R; Schlemmer R; Gust R; Schönenberger H
    Arch Pharm (Weinheim); 2004 Jun; 337(6):335-48. PubMed ID: 15188223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [1, 2-Bis(2, 6-difluoro-3-hydroxyphenyl)ethylene-diamine]platinum(II) complexes, compounds for the endocrine therapy of breast cancer - mode of action II: contribution of drug inactivation, cellular drug uptake and sterical factors in the drug-target interaction to the antitumor activity.
    Schertl S; Hartmann RW; Batzl-Hartmann C; Bernhardt G; Spruss T; Beckenlehner K; Koch M; Krauser R; Schlemmer R; Gust R; Schönenberger H
    Arch Pharm (Weinheim); 2004 Jun; 337(6):349-59. PubMed ID: 15188224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine]- dichloroplatinum(II), a new drug not only parenterally but also orally active in the therapy of breast and prostate cancer.
    Spruss T; Schertl S; Schneider MR; Gust R; Bauer K; Schönenberger H
    J Cancer Res Clin Oncol; 1993; 119(12):707-16. PubMed ID: 8408183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dichloro[1,2-bis(4-hydroxyphenyl)ethylenediamine]platinum(II) complexes: an approach to develop compounds with a specific effect on the hormone-dependent mammary carcinoma.
    Wappes B; Jennerwein M; von Angerer E; Schönenberger H; Engel J; Berger M; Wrobel KH
    J Med Chem; 1984 Oct; 27(10):1280-6. PubMed ID: 6481764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 2-Phenylindole-linked [2-(aminoalkyl)pyridine]dichloroplatinum(II): complexes with a selective action on estrogen receptor positive mammary tumors.
    Knebel NG; von Angerer E
    J Med Chem; 1991 Jul; 34(7):2145-52. PubMed ID: 2066987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [1,2-Bis(2-hydroxyphenyl)ethylenediamine]dichloroplatinum(II), a new compound for the therapy of ovarian cancer. II. Synthesis and preliminary testing of the enantiomeric complexes.
    Bernhardt G; Gust R; Reile H; vom Orde HD; Müller R; Keller C; Spruss T; Schönenberger H; Burgemeister T; Mannschreck A
    J Cancer Res Clin Oncol; 1992; 118(3):201-8. PubMed ID: 1548285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure activity studies on leaving group derivatives of [meso-1,2-bis-(2,6-dichloro-4-hydroxyphenyl)ethylenediamine] platinum(II).
    Gust R; Keilitz R; Krauser R; Schmidt K; Schnurr B
    Arch Pharm (Weinheim); 1999 Aug; 332(8):261-70. PubMed ID: 10489536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.